Aligos Therapeutics (ALGS) Competitors

Aligos Therapeutics (NASDAQ:ALGS) and Protara Therapeutics (NASDAQ:TARA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

Does the media prefer ALGS or TARA?

In the previous week, Protara Therapeutics had 6 more articles in the media than Aligos Therapeutics. MarketBeat recorded 7 mentions for Protara Therapeutics and 1 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.87 beat Protara Therapeutics' score of 1.17 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Very Positive
Protara Therapeutics	Positive

Is ALGS or TARA more profitable?

Protara Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,283.19%. Protara Therapeutics' return on equity of -55.96% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,283.19%	-114.34%	-64.58%
Protara Therapeutics	N/A	-55.96%	-49.06%

Which has stronger valuation & earnings, ALGS or TARA?

Protara Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Protara Therapeutics is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$3.27M	15.01	-$87.68M	-$17.51	-0.46
Protara Therapeutics	N/A	N/A	-$40.42M	-$1.72	-1.90

Do analysts recommend ALGS or TARA?

Aligos Therapeutics presently has a consensus price target of $70.00, indicating a potential upside of 771.73%. Protara Therapeutics has a consensus price target of $20.50, indicating a potential upside of 528.83%. Given Aligos Therapeutics' higher probable upside, equities research analysts clearly believe Aligos Therapeutics is more favorable than Protara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Protara Therapeutics	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.14

Does the MarketBeat Community prefer ALGS or TARA?

Protara Therapeutics received 13 more outperform votes than Aligos Therapeutics when rated by MarketBeat users. Likewise, 70.00% of users gave Protara Therapeutics an outperform vote while only 67.44% of users gave Aligos Therapeutics an outperform vote.

Company	Underperform	Outperform
Aligos Therapeutics	Outperform Votes 29 67.44%	Underperform Votes 14 32.56%
Protara Therapeutics	Outperform Votes 42 70.00%	Underperform Votes 18 30.00%

Do institutionals & insiders hold more shares of ALGS or TARA?

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 38.1% of Protara Therapeutics shares are held by institutional investors. 4.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 8.4% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Which has more risk & volatility, ALGS or TARA?

Aligos Therapeutics has a beta of 2.69, indicating that its stock price is 169% more volatile than the S&P 500. Comparatively, Protara Therapeutics has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.

Summary

Protara Therapeutics beats Aligos Therapeutics on 12 of the 18 factors compared between the two stocks.